Company Projects and Investments - The company has completed the planning and construction of the "Lode Medical Health Smart Industrial Park" project[4] - The company has invested in the establishment of the Chuzhou Lion City Lode Venture Capital Fund with a total fund size of RMB 300 million, with the company holding a 15% stake[5] - The company has invested CNY 11,313,085.43 in the "Deer Medical" project, achieving a project progress of 12.86%[69] - The company plans to invest approximately CNY 1 billion in the "Lude Medical Health Smart Industry Park Project," which includes a research institute, headquarters, international sales center, and production base, with construction already underway[126] - The company has obtained the property rights certificate for the new land and the project filing certificate for the Lude Medical Health Smart Industry Park Project[127] Financial Performance - Total assets increased by 1.68% to ¥490,678,552.02 compared to the end of 2022[28] - Total liabilities rose by 8.41% to ¥101,008,234.16 compared to the end of 2022[28] - Operating revenue decreased by 2.87% to ¥329,263,803.50 in 2023 compared to 2022[28] - Net profit attributable to shareholders decreased by 9.13% to ¥31,689,884.44 in 2023 compared to 2022[28] - The company's cash flow from operating activities decreased by 34.62% to ¥34,025,429.52 in 2023 compared to 2022[28] - The gross profit margin improved to 28.23% in 2023 from 24.47% in 2022[28] - The interest coverage ratio increased significantly to 284.04 in 2023 from 135.46 in 2022[28] - The weighted average return on equity based on net profit was 8.19% in 2023, down from 9.27% in 2022[28] - Cash and cash equivalents decreased by 16.96% to 152.54 million yuan, while accounts receivable increased by 16.27% to 73.61 million yuan[49] - The company’s inventory decreased by 4.82% to 67.03 million yuan, while long-term equity investments increased by 71.27% to 36.71 million yuan[49] Research and Development - The company has obtained an authorized invention patent for a "pulse rotary water flow dental flosser," marking its first invention patent in this product category, enhancing its technological innovation and core competitiveness[6] - Research and development expenses increased by 5.39% to CNY 14,371,588.80, representing 4.36% of total revenue[52] - The company has ongoing R&D projects aimed at expanding its product line, including a high-performance nebulizer and a one-piece upper arm blood pressure monitor, both in the development stage[86] - The total number of patents held by the company increased to 106 from 88 in the previous period, with 9 invention patents[85] - R&D personnel accounted for 14.62% of the total workforce, with a slight decrease in the number of master's degree holders from 8 to 6[84] Market Performance and Sales - The company continues to focus on expanding its international sales through ODM models and developing new business directions in e-commerce[38] - The company’s sales in the South American market saw significant growth, particularly in nebulizers and electronic blood pressure monitors[42] - The company’s focus on cross-border e-commerce has resulted in significant sales growth, with new platforms like eBay contributing positively[42] - Domestic sales revenue increased by 43.49% year-on-year, driven by strong demand for nebulizers and pulse oximeters in the first quarter[61] - The revenue from the new product line, nasal irrigators, grew by 100% compared to the previous year, indicating successful market entry[61] Risk Management and Governance - The company has established a governance structure to mitigate risks associated with the actual controllers potentially making decisions against the company's interests[110] - The company is focused on expanding domestic sales channels and maintaining communication with major clients to explore new markets[107] - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation without significant deficiencies[178] - The company has implemented a shareholder protection mechanism, ensuring equal rights and protections for all shareholders, particularly minority shareholders[179] - The company has adhered to legal procedures for major decisions, ensuring compliance and effective governance throughout its operations[180] Shareholder Information - The total number of unrestricted shares is 72,988,400, representing 41.47% of the total shares[131] - The total number of restricted shares is 103,011,600, representing 58.53% of the total shares[131] - The largest shareholder, Xiang Youliang, holds 39,130,000 shares, accounting for 22.23% of the total shares[134] - The second largest shareholder, Shanghai Lude Industrial Development Co., Ltd., holds 38,944,000 shares, accounting for 22.13% of the total shares[134] - The total number of shareholders holding more than 5% of shares is 10, with a combined holding of 125,279,655 shares, representing 71.19% of the total shares[134] Employee and Management Changes - The total number of employees increased from 554 to 594, with a net addition of 40 employees during the reporting period[164] - The company appointed a new financial director, Zhang Yafei, who has extensive experience in financial management[158] - The total number of employees with a master's degree increased from 11 to 12, while those with a bachelor's degree rose from 89 to 95[164] - The board of directors consists of 9 members, while the supervisory board has 3 members, and there are 6 senior management personnel[152] - The board of directors saw changes, including the appointment of independent director Tang Ronglong and the promotion of Du Wenjun to director and R&D director[156] Legal and Compliance Matters - The company has not engaged in any related party transactions or provided external guarantees during the reporting period[124] - The company has not experienced any major contract disputes that would impact its financial position significantly[125] - The company has completed a significant lawsuit regarding property damage claims against Sunshine Property Insurance Co., Ltd., with a compensation amount of CNY 1,137,045.59, which has been paid[122] - The company is involved in a minor construction contract dispute with Jiangsu Wanjia Construction Engineering Co., Ltd., with an amount of CNY 1,824,964.38, accounting for 0.47% of the net assets[118] Future Outlook - The company anticipates that the next few years will be a "golden period" for rapid development in China's medical device industry[99] - The company aims to strengthen its self-owned brand strategy and increase its market presence through marketing and promotion efforts[101] - The company will continue to invest in research and development to enhance its innovation capabilities for new products and technologies[101] - The company is focused on expanding its market presence, particularly in the mid-to-high-end product segments[86] - The company recognizes the risk of its mechanical sphygmomanometer being replaced by electronic blood pressure monitors, which could lead to a decline in sales revenue from this product line[112]

Financial Performance - Operating revenue for Q1 2024 was ¥65,987,957.04, a decline of 17.08% year-on-year[11] - Net profit attributable to shareholders dropped by 68.39% to ¥3,888,729.21 compared to the same period last year[11] - Total operating revenue for Q1 2024 was CNY 65,987,957.04, a decrease of 17.1% compared to CNY 79,581,657.02 in Q1 2023[37] - Total operating costs for Q1 2024 were CNY 62,060,081.82, down 11.2% from CNY 69,877,217.46 in Q1 2023[37] - Net profit for Q1 2024 was ¥4,272,576.12, down 61.1% from ¥11,015,825.86 in Q1 2023[40] - Total comprehensive income for Q1 2024 was ¥4,272,576.12, down 61.1% from ¥11,015,825.86 in Q1 2023[40] Cash Flow - Cash flow from operating activities showed a net outflow of ¥22,653,367.65, a decrease of 213.20% year-on-year[11] - Cash inflow from operating activities totaled ¥65,201,461.72 in Q1 2024, down 40.6% from ¥109,804,625.54 in Q1 2023[41] - Operating cash flow for Q1 2024 was negative at -¥23,013,106.94, compared to a positive cash flow of ¥27,245,658.48 in Q1 2023, indicating a significant decline in operational performance[43] - The net increase in cash and cash equivalents for Q1 2024 was -¥4,264,549.87, compared to a positive increase of ¥7,851,547.74 in Q1 2023, highlighting a shift in cash management[44] Assets and Liabilities - Total assets decreased by 2.85% to ¥476,676,119.23 compared to the end of last year[11] - The company’s asset-liability ratio decreased to 17.02% from 19.90% at the end of the previous year[11] - Total liabilities decreased to ¥83,117,072.16 from ¥101,008,234.16, a reduction of about 17.7%[33] - The company's equity increased to ¥393,559,047.07 from ¥389,670,317.86, reflecting a growth of approximately 1.0%[33] Research and Development - Research and development expenses increased by 45.46% to ¥3,170,601.68 due to expansion of the R&D team and increased investment in product development[13] - Research and development expenses increased to CNY 3,170,601.68 in Q1 2024, up 45.5% from CNY 2,179,698.65 in Q1 2023[37] - The company is actively engaged in the development of new products and technologies, although specific details were not disclosed in the provided content[28] Shareholder Information - The total number of ordinary shares is 176,000,000, with 6,664 shareholders[16] - The top ten shareholders hold a combined 71.49% of the shares, with the largest shareholder owning 22.23%[17] - There are no pledges or judicial freezes on shares held by shareholders with over 5% ownership[19] - The company has no outstanding preferred stock issues[20] Related Party Transactions - The company reported a daily related party transaction of CNY 27,269.03 for purchasing raw materials in Q1 2024, against an estimated amount of CNY 3,300,000.00[23] - The company sold products worth CNY 1,266,524.77 to a related party in Q1 2024, compared to an estimated CNY 3,100,000.00[23] - The company has no other major related party transactions or significant asset acquisitions during the reporting period[22] Legal and Compliance - There are no significant legal disputes that could adversely affect the company's operations[23] - The company has complied with all necessary internal review procedures for reported matters[22] - The company has fulfilled all previously disclosed commitments related to stock issuance and price stabilization measures[26] Investment Activities - The company reported a fair value gain of ¥313,966.11 in Q1 2024, compared to a loss of -¥77,930.53 in Q1 2023[40] - Investment activities generated a net cash inflow of ¥8,648,717.30 in Q1 2024, a recovery from a net outflow of -¥18,414,099.54 in Q1 2023[44] - The cash outflow for purchasing fixed assets and other long-term assets was ¥9,796,003.67 in Q1 2024, a decrease from ¥18,534,227.40 in Q1 2023, indicating a more conservative investment approach[43]

关于江苏鹿得医疗电子股份有限公司 股东及其他关联方占用资金情况说明的 专项报告 信会师报字[2024]第 ZH10107 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.cov.cn）"进行查验 "法行变用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.cov.cn）"进行查验 。" 关于江苏康得医疗电子股份有限公司 股东及其他关联方占用资金情况说明的专项报告 信会师报字[2024]第 ZH10107 号 江苏鹿得医疗电子股份有限公司全体股东: 我们审计了江苏鹿得医疗电子股份有限公司(以下简称"鹿得医 疗")2023年度的财务报表,包括2023年12月31日的合并及母公司 资产负债表、2023 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注,并于 2024 年 4 月 26 日出具了报告号为信会师报字【2024】第 ZH10105 号的无保留意见审计报告。 鹿得医疗管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号 -- 上市公司资金往来、对外担保的监管要求》(证监会公 告(2 ...

关于江苏鹿得医疗电子股份有限公司 2023年度募集资金存放与使用情况专项 报告的鉴证报告 信会师报字[2024]第 ZH10106 号 一、董事会的责任 鹿得医疗董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号 -- 上市公司募集资金管理和使用的监管要求 (2022年修订)》(证监会公告(2022)15号)、《北京证券交易所 股票上市规则(试行)》、《北京证券交易所上市公司持续监管指引 第9号 -- 募集资金管理》以及《北京证券交易所上市公司持续监管 临时公告格式模板》的相关规定编制募集资金专项报告。这种责任包 括设计、执行和维护与募集资金专项报告编制相关的内部控制,确保 募集资金专项报告真实、准确、完整,不存在虚假记载、误导性陈述 或重大遗漏。 二、注册会计师的责任 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acand.gov.cn）"进行查处 （ ・ 关于江苏鹿得医疗电子股份有限公司2023年度 募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2024]第ZH10106号 江苏鹿得医疗电子股份有限公司全体股东: 我们接受委托,对后附的江苏鹿得医疗电子 ...

证券代码：832278 证券简称：鹿得医疗 公告编号：2024-016 江苏鹿得医疗电子股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经 2020 年 6 月 29 日中国证券监督管理委员会《关于核准江苏鹿得医疗电子 股份有限公司向不特定合格投资者公开发行股票的批复》（证监许可〔2020〕1299 号）核准，公司首次公开发行人民币普通股股票 1,750 万股，每股面值为人民币 1.00 元，发行价格为人民币 8.55 元/股。本次公开发行募集资金总金额为人民币 149,625,000.00 元，扣除相关发行费用为人民币 10,854,429.01 元（不含税），实 际募集资金净额为人民币 138,770,570.99 元，上述募集资金已于 2020 年 7 月 16 日全部汇入指定募集资金专户进行专户存储管理，并由立信会计师事务所（特殊 普通合伙）江苏分所审验，出具了"信会师报 ...

证券代码：832278 证券简称：鹿得医疗 公告编号：2024-026 江苏鹿得医疗电子股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏鹿得医疗电子股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日 召开第四届董事会第四次会议、第四届监事会第四次会议，审议通过《2023 年 年度权益分派预案》议案，现将相关事宜公告如下： 一、权益分派预案情况 根据公司 2024 年 4 月 26 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 67,011,404.02 元，母公司未分配利润为 58,326,240.26 元。 公司本次权益分派预案如下：公司目前总股本为 176,000,000 股，根据扣除 回购专户 1,500,000 股后的 174,500,000 股为基数，以未分配利润向全体股东每 10 股派发现金红利 1 元（含税）。本次权益分派共预计派发 ...

证券代码：832278 证券简称：鹿得医疗 公告编号：2024-013 江苏鹿得医疗电子股份有限公司 2023 年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 2023 年度，本人作为江苏鹿得医疗电子股份有限公司（以下简称"公司"） 的独立董事，严格按照《公司法》《北京证券交易所股票上市规则（试行）》、 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等相关法律法规 及《公司章程》《独立董事工作制度》的规定，认真履行独立董事职责，谨慎、 认真、勤勉地行使公司所赋予独立董事的权利，充分发挥独立董事的作用，切实 维护了公司整体利益和全体股东尤其是中小股东的合法权益。现将 2023 年度履 行独立董事职责的工作情况汇报如下： 一、出席会议情况 （一）出席董事会及股东大会的情况 | 序号 | 委员会类型 | 审议事项 | 意见类型 | | --- | --- | --- | --- | | 1 | 第四届董事会审计委员会第 | 《关于聘任张亚飞女士为公 | 同意 | | | 一 ...

重要内容提示： 拟聘任的会计师事务所：立信会计师事务所（特殊普通合伙） 服务及收费情况：立信会计师事务所（特殊普通合伙）已为公司提供 5 年审 计服务，上期审计收费 40 万元，本期审计收费未确定 一、拟续聘会计师事务所的基本情况 （一）机构信息 证券代码：832278 证券简称：鹿得医疗 公告编号：2024-025 江苏鹿得医疗电子股份有限公司拟续聘 2024 年度会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 公司拟聘任立信会计师事务所（特殊普通合伙）为 2024 年年度的审计机构。 1.基本信息 会计师事务所名称：立信会计师事务所（特殊普通合伙） 成立日期：2011 年 1 月 24 日 组织形式：特殊普通合伙 注册地址：上海市黄浦区南京东路 61 号四楼 首席合伙人：朱建弟 2023 年度末合伙人数量：278 人 2023 年度末注册会计 ...

2023 年度，公司共召开董事会会议 9 次，股东大会会议 4 次，本人出席会 议情况如下： 证券代码：832278 证券简称：鹿得医疗 公告编号：2024-015 江苏鹿得医疗电子股份有限公司 2023 年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 2023 年度，本人作为江苏鹿得医疗电子股份有限公司（以下简称"公司"） 的独立董事，严格按照《公司法》《北京证券交易所股票上市规则（试行）》、 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等相关法律法规 及《公司章程》《独立董事工作制度》的规定，认真履行独立董事职责，谨慎、 认真、勤勉地行使公司所赋予独立董事的权利，充分发挥独立董事的作用，切实 维护了公司整体利益和全体股东尤其是中小股东的合法权益。现将 2023 年度履 行独立董事职责的工作情况汇报如下： 一、出席会议情况 （一）出席董事会及股东大会的情况 | 独立董事 | 应出席董事 | 实际出席董事 | 应列席股东大 | 实际列席股东 | | --- | -- ...

证券代码：832278 证券简称：鹿得医疗 公告编号：2024-009 江苏鹿得医疗电子股份有限公司 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 26 日 2.会议召开地点：南通工厂会议室 3.会议召开方式：现场及电话连线 4.发出董事会会议通知的时间和方式：2024 年 4 月 16 日以书面方式发出 5.会议主持人：董事长项友亮 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 会议召集、召开、议案审议程序符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于 2023 年年度报告及年度报告摘要的议案》 1.议案内容： 根据《北京证券交易所股票上市规则（试行）》等法律、法规及《公司章程》 的规定，公司编制了《江苏鹿得医疗电子股 ...